GCA
ABBV icon

Genesee Capital Advisors’s AbbVie ABBV Stock Holding History

Genesee Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.22M Sell
4,844
-211
-4% -$45.4K 0.38% 55
2026
Q1 		$1.1M Buy
5,055
+2,161
+75% +$479K 0.46% 49
2025
Q4 		$661K Buy
2,894
+526
+22% +$120K 0.27% 70
2025
Q3 		$548K Sell
2,368
-2
-0.1% -$407 0.24% 72
2025
Q2 		$440K Sell
2,370
-126
-5% -$23.4K 0.2% 80
2025
Q1 		$523K Buy
2,496
+177
+8% +$34.4K 0.26% 78
2024
Q4 		$412K Buy
2,319
+18
+0.8% +$3.31K 0.19% 84
2024
Q3 		$454K Buy
2,301
+15
+0.7% +$2.8K 0.22% 82
2024
Q2 		$392K Buy
2,286
+166
+8% +$27.5K 0.19% 81
2024
Q1 		$386K Buy
2,120
+240
+13% +$41.4K 0.21% 79
2023
Q4 		$291K Buy
1,880
+482
+34% +$70.3K 0.18% 83
2023
Q3 		$208K Buy
+1,398
New +$205K 0.15% 84
2023
Q2 		– Sell
-1,713
Closed -$273K – 89
2023
Q1 		$273K Buy
+1,713
New +$262K 0.19% 71
2022
Q4 		– Sell
-2,496
Closed -$335K – 80
2022
Q3 		$335K Buy
2,496
+183
+8% +$26.3K 0.26% 64
2022
Q2 		$354K Buy
2,313
+20
+0.9% +$3.06K 0.25% 70
2022
Q1 		$372K Buy
2,293
+184
+9% +$26.7K 0.19% 79
2021
Q4 		$286K Buy
2,109
+22
+1% +$2.6K 0.14% 88
2021
Q3 		$225K Buy
+2,087
New +$238K 0.11% 103
2021
Q2 		– Sell
-2,044
Closed -$221K – 44
2021
Q1 		$221K Buy
2,044
+24
+1% +$2.57K 0.13% 82
2020
Q4 		$216K Buy
+2,020
New +$194K 0.14% 75
2020
Q3 		– Sell
-9,655
Closed -$947K – 76
2020
Q2 		$947K Buy
+9,655
New +$850K 0.88% 38

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Genesee Capital Advisors's ABBV Position: Q2 2026 in Review

Genesee Capital Advisors reduced its AbbVie (ABBV) stake by 4.2% in Q2 2026, selling an estimated $45.4K and leaving 4,844 shares worth $1.22M. The position accounts for 0.38% of the portfolio, ranked #55.

Genesee Capital Advisors first reported a position in ABBV in Q2 2020 and has held it in 21 quarters since. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Genesee Capital Advisors held 4,844 shares of AbbVie worth $1.22M as of Q2 2026.
  • Genesee Capital Advisors sold 211 AbbVie shares in Q2 2026, an estimated $45.4K.
  • AbbVie made up 0.38% of Genesee Capital Advisors's portfolio in Q2 2026, its #55 holding.
  • Genesee Capital Advisors first reported a position in AbbVie in Q2 2020 and has held it in 21 quarters since.
  • 4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Genesee Capital Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.